Genetic control of cell differentiation in the skeleton

Current Opinion in Cell Biology

Volumn 10, Issue 5, 1998, Pages 614-619

  Ducy, Patricia ^a   Karsenty, Gérard ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; PROTEIN; UNCLASSIFIED DRUG;

BONE DEVELOPMENT; CARTILAGE CELL; CELL DIFFERENTIATION; GENE EXPRESSION; GENETIC MANIPULATION; GENETIC REGULATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; REVIEW; SKELETON;

EID: 0031671856     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(98)80037-9     Document Type: Article

References (50)

1. Cohn MJ, Tickle C. Limbs: a model for pattern formation within the vertebrate body plan. Trends Genet. 12:1996;253-258.
2. Hogan BLM. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 10:1996;1580-1594.
3. Tabin CJ. Retinoids, homeoboxes, and growth factors: toward molecular models for limb development. Cell. 66:1991;199-217.
4. Hall BK, Miyake T. The membranous skeleton: the role of cell condensations in vertebrate skeletogenesis. Anat Embryol. 186:1992;107-124.
5. Horton WA. Morphology of connective tissue: cartilage. Connective Tissue and Its Heritable Disorders. 1993;73-84 Wiley-Liss, Inc, New York
6. Lui VC, Ng LJ, Nicholls J, Tam PP, Cheah KS. Tissue-specific and differential expression of alternatively spliced alpha 1(II) collagen mRNAs in early human embryos. Dev Dyn. 203:1995;198-211.
7. Ryan MC, Sandell LJ. Differential expression of a cystein-rich domain in the amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA. J Biol Chem. 265:1990;10334-10339.
8. Sandell LJ, Morris N, Robbins JR, Goldring MB. Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide. J Cell Biol. 114:1991;1307-1319.
9. Luo G, D'Souza R, Hogue D, Karsenty G. The matrix Gla protein gene is a marker of the chondrogenesis cell lineage during mouse development. J Bone Miner Res. 10:1995;325-334.
10. Thorogood P. Differentiation and morphogenesis of cranial skeletal tissues. Hanken J, Hall BK. The Skull. 1993;University of Chicago Press, Chicago.
11. Grigoriadis AE, Heersche JNM, Aubin JE. Analysis of chondroprogenitor frequency and cartilage differentiation in a novel family of clonal chondrogenic rat cell lines. Differentiation. 60:1996;299-307.
12. Suda T, Takaharashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev. 13:1992;66-80.
13. Ng LJ, Wheatley S, Muscat GE, Conway-Campbell J, Bowles J, Wright E, Bell DM, Tam PP, Cheah KS, Koopman P. SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse. of outstanding interest Dev Biol. 183:1997;108-121 This paper provides an extensive study of Sox9 and type II collagen gene coexpression during mouse development. This paper also shows that Sox9 can bind and activate transcription through a consensus SOX/SRY element.
14. Zhao Q, Eberspaecher H, Lefebvre V, De Crombrugghe B. Parallel expression of Sox9 and Col2a1 in cells undergoing chondrogenesis. Dev Dyn. 209:1997;377-386.
15. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell. 79:1994;1111-1120.
16. Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B. SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. of outstanding interest Mol Cell Biol. 17:1997;2336-2346 Identification of a Sox9 binding site in the first intron of the mouse type II collagen gene is reported here. In vitro and in vivo demonstration of the transcriptional activity of this element is also described.
17. Bell DM, Leung KK, Wheatley SC, Ng LJ, Zhou S, Ling KW, Sham MH, Koopman P, Tam PP, Cheah KS. SOX9 directly regulates the type-II collagen gene. of outstanding interest Nat Genet. 16:1997;174-178 This paper describes the in vitro characterization of a Sox9 binding site in the first intron of the mouse type II collagen gene. It also provides a demonstration in vivo that ectopic expression of Sox9 can transactivate type II collagen gene expression.
18. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 237:1987;893-896.
19. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VL, Kronenberg HM, Mulligan RC. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev. 8:1994;277-289.
20. Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, Karperien M, Defize LHK, Ho C, Mulligan RC, et al. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science. 273:1996;663-666.
21. Schipani E, Kruse K, Juppner H. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science. 268:1995;98-100.
22. Bitgood MJ, McMahon AP. Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev Biol. 172:1993;126-138.
23. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science. 273:1996;613-622.
24. Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, Beachy PA. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature. 383:1996;407-413.
25. Naski MC, Wang Q, Xu J, Ornitz DM. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet. 13:1996;233-237.
26. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet. 12:1996;390-397.
27. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chomdrocytes. of outstanding interest Cell. 93:1998;411-422 Targeted inactivation of the Gelatinase B gene in mice is described in this paper. Homozygous mutants first exhibit delayed apoptosis of the hypertrophic chondrocytes, vascularization and ossification. In older animals these process take place aberrantly. Gelatinase B is shown to be synthesized by a novel cell type of bone marrow origin, the chondroclast.
28. Ducy P, Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol. 15:1995;1858-1869.
29. Geoffroy V, Ducy P, Karsenty G. A PEBP2/AML-1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element. J Biol Chem. 270:1995;30973-30979.
30. Merriman HL, van Wijnen AJ, Hiebert S, Bidwell JP, Fey E, Lian J, Stein J, Stein GS. The tissue-specific nuclear matrix protein, NMP-2, is a member of the AML/CBF/PEBP2/Runt domain transcription factor family: interactions with the osteocalcin gene promoter. Biochemistry. 34:1995;13125-13132.
31. Gergen JP, Wieschaus E. The localized requirements for a gene affecting segmentation in Drosophila: analysis of larvae mosaic for runt. Dev Biol. 109:1985;321-335.
32. Kagoshima H, Shigesada K, Satake M, Ito Y, Miyoshi H, Ohki M, Pepling M, Gergen P. The Runt domain identifies a new family of heteromeric transcriptional regulators. Trends Genet. 9:1993;338-341.
33. Ito Y, Bae S-C. The runt domain transcription factor PEBP2/CBF, and its involvment in human leukemia. Yaniv M, Ghysdael J. Oncogenes as Transcriptional Regulators. 2:1997;107-132 Birkhauser Verlag, Basel.
34. Satake M, Nomura S, Yamagushi-Iwai Y, Takahama Y, Hashimoto Y, Niki M, Kitamura Y, Ito Y. Expression of the runt domain-encoding PEBP2a genes in T cells during thymic development. Mol Cell Biol. 15:1995;1662-1670.
35. Ducy P, Zhang R, Geoffroy V, Ridall A, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. of outstanding interest Cell. 89:1997;747-754 This paper reports the cloning of Osf2/Cbfa1 cDNA and provides molecular evidence that it acts as a transcriptional activator of osteoblast differentiation.
36. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GWH, Beddington RSP, Mundlos S, Olsen BR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. of outstanding interest Cell. 89:1997;765-771 This paper shows the requirement of Cbfa1 for osteoblast differentiation during embryogenesis using targeted disruption of the Cbfa1 gene in mice. It also establishes the genetic link between Cbfa1 and the CCD phenotype in mice.
37. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao Y-H, Inada M, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. of outstanding interest Cell. 89:1997;755-764 This study shows the requirement of Cbfa1 for osteoblast differentiation and osteoblast-specific gene expression during embryogenesis using targeted disruption of the Cbfa1 gene in mice.
38. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JHM, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. of outstanding interest Cell. 89:1997;773-779 This paper is particularly important because it shows that cleidocranial dysplasia is caused by haploinsufficiency. It reports the characterization of deletions, stop codon and insertion mutations in the CBFA1 gene of cleidocranial dysplasia patients.
39. Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Geoffroy V, Ducy P, Karsenty G. Missense mutations abolishing DNA binding OSF2/CBFA1 in patients affected with cleidocranial dysplasia. of outstanding interest Nat Genet. 16:1997;307-311 This paper reports the characterization of missense mutations in the DNA-binding domain encoding region of the CBFA1 gene in cleidocranial dysplasia patients.
40. Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R, Teitelbaum SL. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. of outstanding interest Nature. 386:1997;81-84 This paper reports the targeted inactivation of the PU.1 gene in mice. Homozygous PU.1 mutants present with severe osteopetrosis and lack both macrophages and osteoclasts.
41. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 345:1990;442-444.
42. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. of outstanding interest Cell. 89:1997;309-319 Identification of osteoprogerin (OPG), a soluble factor related to the TNF receptor family, that blocks osteoclastogenesis in vitro is reported. Overexpression of OPG gene in mice leads to increased bone density.
43. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. of special interest Genes Dev. 12:1998;1260-1268 Targeted inactivation of the osteoprotegerin (OPG) gene in mice is described. Homozygous mutants of OPG show a severe decrease in bone density.
44. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Brugess T, Elliot R, Colombero A, Elliot G, Scully S, Hsu H, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. of outstanding interest Cell. 93:1998;165-176 Identification of the osteoprotegerin ligand (OPGL) is reported here. OPGL is related to the TNF receptor family but can exists as a transmembrane or soluble form. OPGL activates osteoclast maturation in vitro and enhances bone resorption in vivo.
45. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. of outstanding interest Proc Natl Acad Sci USA. 95:1998;3597-35602 This paper demonstrates purification and cloning of the osteoclast differentiation factor (ODF) gene. In vitro experiments show that ODF is the osteoprotegerin ligand and that it mediates osteoclast differentiation.
46. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF. Bone and haematopoietic defects in mice lacking c-fos. Nature. 360:1992;741-745.
47. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 266:1994;443-448.
48. Johnson RS, Spiegelman BM, Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell. 71:1992;577-586.
49. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U. Requirement for NF-kappa B in osteoclast and B-cell development. of special interest Genes Dev. 11:1997;3482-3496 Simultaneous targeted inactivation of the genes encoding the p50 and p52 subunits of NFκB is described. Doubly homozygous mutants present severe osteopetrosis due to an absence of osteoclasts. B cells are also absent.
50. Hodgkinson CA, Moore KJ, Nakayama A, Steingrimsson E, Copeland NG, Jenkins NA, Arnheiter H. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell. 74:1993;395-404.